Future studies defining CIP2A as a useful therapeutic biomarker for breast cancer patients, as well as the detailed mechanism by which bortezomib inhibits CIP2A may lead to further progress in the development of molecular-targeted therapy for TNBC. The gene discussed is CIP2A; the disease is breast cancer.